Financials Acrobiosystems Co.,Ltd.

Equities

301080

CNE100004S13

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-06-05 EDT			5-day change	1st Jan Change
36.77 ^CNY	-4.99%		-5.28%	-37.61%

05-15	Acrobiosystems Co.,Ltd. Approves Cash Dividend for 2023	CI
04-24	Acrobiosystems Co.,Ltd. Proposes Final Cash Dividend for 2023	CI

Valuation

Fiscal Period: December	2021	2022	2023	2024	2025	2026
Capitalization ¹	16,890	8,215	7,071	4,386	-	-
Enterprise Value (EV) ¹	16,890	8,215	7,071	4,386	4,386	4,386
P/E ratio	76.8 x	60.5 x	46 x	23.4 x	17.3 x	16.7 x
Yield	0.71%	1.46%	1.53%	1.93%	2.44%	2.28%
Capitalization / Revenue	43.9 x	17.3 x	13 x	6.83 x	5.4 x	4.7 x
EV / Revenue	43.9 x	17.3 x	13 x	6.83 x	5.4 x	4.7 x
EV / EBITDA	81.1 x	34 x	35.3 x	22.8 x	15.8 x	16.1 x
EV / FCF	-	-	-404 x	37.8 x	26.3 x	20.3 x
FCF Yield	-	-	-0.25%	2.65%	3.81%	4.93%
Price to Book	6.85 x	3.21 x	2.73 x	1.63 x	1.51 x	1.46 x
Nbr of stocks (in thousands)	120,000	120,000	119,970	119,726	-	-
Reference price ²	140.8	68.46	58.94	36.77	36.77	36.77
Announcement Date	22-04-14	23-04-25	24-04-23	-	-	-

¹CNY in Million²CNY

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	-	385	474.4	543.7	642.6	812.4	932.2
EBITDA ¹	-	208.2	241.7	200.1	192.4	277	271.8
EBIT ¹	-	195.6	216.5	161.1	187.9	255	281.2
Operating Margin	-	50.82%	45.62%	29.63%	29.24%	31.39%	30.17%
Earnings before Tax (EBT) ¹	-	195.4	215	160.7	187.3	254.5	280.6
Net income ¹	115.9	174.2	203.7	153.6	188.3	254.5	264
Net margin	-	45.25%	42.94%	28.25%	29.3%	31.33%	28.31%
EPS ²	1.287	1.834	1.132	1.280	1.569	2.120	2.200
Free Cash Flow ¹	-	-	-	-17.49	116	167	216
FCF margin	-	-	-	-3.22%	18.05%	20.56%	23.17%
FCF Conversion (EBITDA)	-	-	-	-	60.31%	60.3%	79.47%
FCF Conversion (Net income)	-	-	-	-	61.62%	65.62%	81.83%
Dividend per Share ²	-	1.000	1.000	0.9000	0.7100	0.8967	0.8400
Announcement Date	21-04-08	22-04-14	23-04-25	24-04-23	-	-	-

¹CNY in Million²CNY

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2024 Q1
Net sales ¹	146
EBITDA	-
EBIT	-
Operating Margin	-
Earnings before Tax (EBT)	-
Net income ¹	30.67
Net margin	21.01%
EPS	-
Dividend per Share	-
Announcement Date	24-04-23

¹CNY in Million

Estimates

Balance Sheet Analysis

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-
Free Cash Flow ¹	-	-	-	-17.5	116	167	216
ROE (net income / shareholders' equity)	-	27.4%	8.13%	5.98%	7.19%	8.53%	8.72%
ROA (Net income/ Total Assets)	-	6.85%	7.72%	-	5.97%	6.97%	7.8%
Assets ¹	-	2,545	2,640	-	3,155	3,653	3,384
Book Value Per Share ²	-	20.60	21.40	21.60	22.50	24.40	25.10
Cash Flow per Share ²	-	1.150	1.680	0.9300	1.370	1.620	2.170
Capex ¹	-	61.7	284	129	82	60.4	74.1
Capex / Sales	-	16.01%	59.85%	23.67%	12.77%	7.44%	7.95%
Announcement Date	21-04-08	22-04-14	23-04-25	24-04-23	-	-	-

¹CNY in Million²CNY

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Acrobiosystems Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

36.77 CNY

Average target price

56.78 CNY

Spread / Average Target

+54.41%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ACROBIOSYSTEMS CO.,LTD.	-37.61%	608M
ELI LILLY AND COMPANY	+46.11%	754B
NOVO NORDISK A/S	+41.83%	630B
JOHNSON & JOHNSON	-6.16%	352B
MERCK & CO., INC.	+20.13%	331B
ABBVIE INC.	+9.15%	298B
ASTRAZENECA PLC	+18.74%	250B
NOVARTIS AG	+12.15%	217B
ROCHE HOLDING AG	-0.57%	216B
AMGEN INC.	+6.26%	164B

Other Pharmaceuticals